Centessa Pharmaceuticals plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 11 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
Share-based compensation expense
Loss on extinguishment of debt
Depreciation and amortization
Amortization of discount of marketable securities
Change in fair value of financial instruments
Amortization of debt issuance costs and exit fee of long-term debt
Change in deferred taxes
Changes in operating assets and liabilities:
Tax incentive receivable
Prepaid expenses and other assets
Operating leases, net
Accounts payable
Accrued expenses and other liabilities
Other, net

Net cash used in operating activities
Cash flows from investing activities:
Cash acquired upon acquisition of Centessa Subsidiaries, net of cash paid
Purchases of investments in marketable securities
Proceeds from maturities of investments in marketable securities
Purchase of property and equipment
Other, net
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from the sale of convertible preferred shares, net of issuance costs
Proceeds from the sale of ordinary shares in connection with initial public offering, net of issuance costs paid in cash
Proceeds from issuance of shares, net of issuance costs
Underwriter Offering
ATM Program
Total proceeds from issuance of shares, net of issuance costs
Repayment of debt
Proceeds from issuance of debt, net of issuance costs
Payment of employee withholding taxes related to withheld shares for stock based compensation plans
Proceeds from option exercises
Other, net
Net cash provided by financing activities

Effect of exchange rate on cash, cash equivalents, and restricted cash
Net (decrease) increase in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosure:
Interest paid
Income taxes paid
Operating lease payments reducing operating lease liabilities
Right-of-use assets obtained in exchange for operating lease liabilities - noncash
Issuance of ordinary shares to settle outstanding contingent value rights
Issuance of ordinary shares upon acquisition of Centessa Subsidiaries
Issuance of contingent value rights upon acquisition of Centessa Subsidiaries
Issuance of Series A convertible preferred shares
Forgiveness of convertible term loan

Comments